If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the diagnostic process for progressive multifocal leukoencephalopathy (PML) is critical. The medical community has developed structured testing protocols to detect PML early, building on decades of research into immune-modulating therapies. This page outlines the clinical workup, including MRI and CSF analysis, and the typical timeline for diagnosis.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of the risk and the need for careful patient monitoring. PML is caused by reactivation of the JC virus in immunocompromised individuals. Tysabri works by blocking the migration of immune cells into the central nervous system, which can reduce inflammation but also impairs immune surveillance against the JC virus. The FDA label identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who test positive for anti-JCV antibodies have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. Prior use of immunosuppressive medications further elevates the risk. Clinical presentation of PML can be subtle and may include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. The FDA label advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically involves brain imaging, cerebrospinal fluid analysis for JC virus DNA, and sometimes brain biopsy. Early detection is critical because PML can progress rapidly, leading to severe disability or death.
The FDA Adverse Event Reporting System (FAERS) database lists numerous adverse events associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they highlight the range of neurological symptoms that may be reported by patients. In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate that PML can occur even with relatively short exposure. The timeline between Tysabri exposure and PML onset varies. The boxed warning notes that risk increases with longer treatment duration, but cases have been reported after as few as eight doses. Patients and healthcare providers must remain vigilant throughout treatment. The FDA label emphasizes that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This means that the decision to use Tysabri requires a careful risk-benefit analysis, particularly for patients with risk factors. For patients who develop PML, the consequences are often devastating. The boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors may experience permanent neurological deficits, including cognitive impairment, motor dysfunction, and vision loss. The emotional and financial burden on patients and their families can be substantial.
Given the severity of PML, the adequacy of warnings is a critical concern. The FDA has mandated a boxed warning and a restricted distribution program called the TOUCH Prescribing Program to ensure that patients are informed of the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients may feel that the warnings were insufficient or that they were not fully informed of the risk before starting treatment. This can lead to legal considerations, as affected patients may seek compensation for their injuries through product liability claims. An attorney experienced in Tysabri-related PML cases can help patients navigate the legal process, including gathering medical records, documenting the timeline of exposure and harm, and assessing whether the manufacturer provided adequate warnings. In summary, Tysabri is associated with a known risk of PML, a severe and often fatal brain infection. The FDA label identifies specific risk factors and emphasizes the need for monitoring. Patients who develop PML may face life-altering consequences, and legal options may be available for those who believe the warnings were inadequate. It is essential for patients and healthcare providers to remain informed about the risks and to act promptly if symptoms suggestive of PML arise.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell migration into the central nervous system.
The FDA label identifies three key risk factors: presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants. These factors increase the likelihood of PML.
Patients who developed PML may pursue product liability claims if they believe the manufacturer failed to provide adequate warnings. An experienced attorney can help gather evidence, document the timeline, and assess the strength of the case.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.